Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,582 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
INGAP Peptide
Drug
Lead sponsor
GMP Endotherapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
4
States / cities
San Diego, California • Washington D.C., District of Columbia • Durham, North Carolina + 1 more
Completed Not applicable Interventional Results available

Decreasing Stress in Diabetes

NCT04016415
Conditions
Stress, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Mindfulness Based Stress Reduction, Stress Management Education
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Diabetes Type 1
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Type 1 Diabetes
Interventions
Pramlintide, Glargine, Lispro, Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Interventions
Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Completed Phase 3 Interventional Results available

Mylan Insulin Aspart Study

NCT03760068
Conditions
Diabetes Mellitus, Type 1
Interventions
MYL-1601D Product, FlexPen NovoLog®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
158
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 125 more
Conditions
Type 1 Diabetes
Interventions
Stem Cell Educator therapy
Combination Product
Lead sponsor
Throne Biotechnologies Inc.
Industry
Eligibility
10 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Paramus, New Jersey
Conditions
Diabetic Nephropathies
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Ann Arbor, Michigan + 1 more
Conditions
Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis
Interventions
PiCASO Intervention Group, Sham Comparator: Attention Control Group
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 22 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Completed No phase listed Observational Accepts healthy volunteers

Bone Health in Type 1 Diabetes

NCT00651196
Conditions
Type 1 Diabetes, Osteoporosis
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Hypoglycemia Unawareness, Diabetes Mellitus, Type 1
Interventions
Glucagon, Placebo
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
21 Years to 64 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Atlanta, Georgia + 1 more
Conditions
Type 1 Diabetes Mellitus
Interventions
BIOD-123, Lispro (Humalog)
Drug
Lead sponsor
Biodel
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Anaheim, California • Chula Vista, California • Concord, California + 28 more
Completed Phase 4 Interventional Results available

Use of Santyl in Diabetic Foot Ulcers

NCT02581488
Conditions
Diabetic Foot, Foot Ulcer, Diabetic
Interventions
Santyl, Product containing silver
Biological · Other
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Sylmar, California • Melbourne, Florida • Baltimore, Maryland + 8 more
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia
Terminated Phase 2 Interventional Results available

Carvedilol in Treating Hypoglycemia Unawareness

NCT03538015
Conditions
Hypoglycemia Unawareness
Interventions
Carvedilol 3.125 mg, Carvedilol 2.5 mg, Placebo capsule
Drug
Lead sponsor
Owen Chan, PhD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Concord, California • Escondido, California • Walnut Creek, California + 5 more
Conditions
Diabetes Mellitus Type 1
Interventions
ORMD-0801 Capsules, Placebo
Biological · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Tustin, California
Conditions
Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
Interventions
twiist Automated Insulin Delivery System
Device
Lead sponsor
Deka Research and Development
Industry
Eligibility
6 Years and older
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
No treatment given, survey
Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Diabetes Mellitus, Type 1
Interventions
Blood Glucose Awareness Training for Parents
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 11 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Conditions
Diabetes Mellitus, Type I
Interventions
Dexcom G4 or G5 Platinum CGM system, Dexcom G4 or G5 Platinum CGM system with Share
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Completed Phase 2 Interventional Results available

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

NCT02293837
Conditions
Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
Interventions
Tocilizumab (TCZ), Placebo, Standard of Care
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 14 more
Conditions
Type 1 Diabetes (T1D)
Interventions
Sotagliflozin Low Dose, Sotagliflozin High Dose, Dual Continuous Glucose and Ketone Monitor
Drug · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
La Jolla, California
Conditions
Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions
G-Pen, Lilly Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more